Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Legal Officer | October 02, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date October 02, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,110 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 5,786 · Balance 14,896 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2026-10-02 · Sale · Disposed 5,786 · Balance 9,110 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2034-02-12 | Direct | 111,251 |
Reported balance
After 2026-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-02 · Exercise / conversion · Disposed 5,786 · Balance 111,251 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2021 Filed Apr 13, 2021 21:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-026458 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,466 Underlying: Common Stock · 1,200 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 21:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,200 | $27.20 | $32,640.00 |
DisclosureSEC source: 0001209191-21-026458 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $27.11 and the highest price at which shares were sold was $28.18. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 12, 2021 Filed Apr 13, 2021 21:20 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,200 | $1.86 | $2,232.00 |
DisclosureSEC source: 0001209191-21-026458 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-019870 · doc4.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,666 Underlying: Common Stock · 2,000 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F7 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 395 | $44.11 | $17,424.64 |
DisclosureSEC source: 0001209191-21-019870 · doc4.xml · nonDerivative · entry 5 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F6 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $43.59 and the highest price at which shares were sold was $44.31. F2 · balance_after: Includes 805 shares of Common Stock acquired by the Reporting Person on February 12, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 405 | $42.67 | $17,279.73 |
DisclosureSEC source: 0001209191-21-019870 · doc4.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $42.15 and the highest price at which shares were sold was $43.15. F2 · balance_after: Includes 805 shares of Common Stock acquired by the Reporting Person on February 12, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 300 | $41.13 | $12,339.00 |
DisclosureSEC source: 0001209191-21-019870 · doc4.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,605 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $40.99 and the highest price at which shares were sold was $41.30. F2 · balance_after: Includes 805 shares of Common Stock acquired by the Reporting Person on February 12, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 900 | $39.44 | $35,496.00 |
DisclosureSEC source: 0001209191-21-019870 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,905 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $39.39 and the highest price at which shares were sold was $39.84. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6) to this Form 4. F2 · balance_after: Includes 805 shares of Common Stock acquired by the Reporting Person on February 12, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $1.86 | $3,720.00 |
DisclosureSEC source: 0001209191-21-019870 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · balance_after: Includes 805 shares of Common Stock acquired by the Reporting Person on February 12, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001209191-21-012664 · doc4.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,666 Underlying: Common Stock · 2,000 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · derivative.exercise_date: The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 500 | $37.03 | $18,516.00 |
DisclosureSEC source: 0001209191-21-012664 · doc4.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $36.46 and the highest price at which shares were sold was $37.30. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,100 | $35.86 | $39,444.35 |
DisclosureSEC source: 0001209191-21-012664 · doc4.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.42 and the highest price at which shares were sold was $36.41. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $34.48 | $13,790.00 |
DisclosureSEC source: 0001209191-21-012664 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $33.88 and the highest price at which shares were sold was $34.85. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:08 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $1.86 | $3,720.00 |
DisclosureSEC source: 0001209191-21-012664 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 11, 2021 Filed Feb 13, 2021 00:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $38.97 | $0.00 |
DisclosureSEC source: 0001209191-21-010441 · doc4.xml · derivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares monthly beginning March 11, 2021 until the option is fully vested on February 11, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.